This is my archive
Company’s first-in-class PDE9 inhibitor for heart failure and first-in-class CaMKII inhibitor move into later-stage clinical trials in cardiovascular diseases Financing enables further expansion of pipeline and acceleration of capabilities as a cardiovascular drug innovator Financing enables further expansion of pipeline and acceleration of capabilities as a cardiovascular drug innovator July… Read More
Series A co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight Company is developing a new class of genomic medicines based on naturally occurring genetic elements that may be… Read More
Financing led by BVF Partners LP, with participation from new investors RA Capital Management, Cormorant Asset Management, Soleus Capital, Delos Capital and existing investors aMoon Fund and Blackstone Multi-Asset Investing, among other new and existing investors Funds will be used to support ongoing and planned Phase 2a and 2b clinical… Read More
Financing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital, and other new and existing investors Proceeds to support ongoing mid- to late-stage clinical development programs for Company’s lead I&I product candidate, obexelimab WALTHAM, Mass, May 7, 2024 (GLOBE NEWSWIRE) – Zenas BioPharma,… Read More
Financing includes nine new investors and was led by New Enterprise Associates, Deep Track Capital, Sofinnova Investments, and Sands Capital Proceeds to support advancing AVZO-021, a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor SAN DIEGO, Calif., March 26, 2024 – Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next… Read More
October 9, 2023, San Diego and Shanghai – Sirius Therapeutics today announced that it has completed a US$60 million Series B financing to advance the clinical development of the Company’s novel siRNA therapeutics and the continued innovation of the next-generation RNA delivery technologies. This financing round was led by Hankang… Read More
Secured financing advances Instylla’s clinical trials and commercialization readiness BEDFORD, Mass., Aug. 15, 2023 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the closing of a $30 million financing round. This financing round was led by new investor, Delos Capital, with… Read More
– Proceeds to support the development of Eccogene’s clinical-stage metabolic pipeline including ECC5004, a small molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and ECC4703, a THRβ full agonist for NASH and lipid disorders Boston/Shanghai/June 12nd, 2023 — Eccogene, Inc., a clinical-stage biotechnology company developing innovative therapeutic solutions for metabolic… Read More
Previously announced $85 million financing extended by $50 million BOSTON, May 16, 2023 – Ensoma, a genomic medicines company developing one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the closing of an extension of its Series B financing by $50 million, bringing the total size of… Read More
Proceeds to accelerate commercialization and pipeline expansion of novel FLASH™ Aorto-Ostial Angioplasty System CAMPBELL, Calif., Feb. 8, 2023 /PRNewswire/ — Ostial Corporation (Ostial), a private medical technology company focused on addressing the clinical challenges of aorto-ostial interventions, today announced the raise of $7.5M in growth funding led by Delos… Read More
